Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07672483 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotableRecruitment openedStart date: Oct 13, 2026 to Oct 14, 2026Show 1 more changeShow less
Start date: Oct 13, 2026 to Oct 14, 2026
MinorStart date: Oct 12, 2026 to Oct 13, 2026
NotableTrial status: Not Yet Recruiting to RecruitingStart date: Oct 11, 2026 to Oct 12, 2026 · Site details revisedShow 2 more changesShow less
Start date: Oct 11, 2026 to Oct 12, 2026
Site details revised
MinorStart date: Oct 8, 2026 to Oct 11, 2026
MinorStart date: Oct 7, 2026 to Oct 8, 2026
Show 45 earlier versionsHide 45 earlier versions
MinorStart date: Oct 6, 2026 to Oct 7, 2026
MinorStart date: Oct 5, 2026 to Oct 6, 2026
MinorStart date: Oct 4, 2026 to Oct 5, 2026
MinorStart date: Sep 20, 2026 to Oct 4, 2026
MinorStart date: Sep 17, 2026 to Sep 20, 2026v55
MinorStart date: Sep 16, 2026 to Sep 17, 2026v54
MinorStart date: Sep 15, 2026 to Sep 16, 2026v53
MinorStart date: Sep 14, 2026 to Sep 15, 2026v52
MinorStart date: Sep 10, 2026 to Sep 14, 2026v51
MinorStart date: Sep 9, 2026 to Sep 10, 2026v50
MinorStart date: Sep 8, 2026 to Sep 9, 2026v49
MinorStart date: Sep 7, 2026 to Sep 8, 2026v48
MinorStart date: Sep 6, 2026 to Sep 7, 2026v47
MinorStart date: Sep 3, 2026 to Sep 6, 2026v46
MinorStart date: Sep 2, 2026 to Sep 3, 2026v45
MinorStart date: Sep 1, 2026 to Sep 2, 2026v44
MinorStart date: Aug 31, 2026 to Sep 1, 2026v43
MinorStart date: Aug 30, 2026 to Aug 31, 2026v42
MinorStart date: Aug 27, 2026 to Aug 30, 2026v41
MinorStart date: Aug 26, 2026 to Aug 27, 2026v40
MinorStart date: Aug 25, 2026 to Aug 26, 2026v39
MinorStart date: Aug 24, 2026 to Aug 25, 2026v38
MinorStart date: Aug 23, 2026 to Aug 24, 2026v37
MinorStart date: Aug 20, 2026 to Aug 23, 2026v36
MinorStart date: Aug 19, 2026 to Aug 20, 2026v35
MinorStart date: Aug 18, 2026 to Aug 19, 2026v34
MinorStart date: Aug 17, 2026 to Aug 18, 2026v33
MinorStart date: Aug 16, 2026 to Aug 17, 2026v32
MinorStart date: Aug 13, 2026 to Aug 16, 2026v31
MinorStart date: Aug 12, 2026 to Aug 13, 2026v30
MinorStart date: Aug 11, 2026 to Aug 12, 2026v29
MinorStart date: Aug 10, 2026 to Aug 11, 2026v28
MinorStart date: Aug 7, 2026 to Aug 10, 2026v27
MinorStart date: Aug 6, 2026 to Aug 7, 2026v26
MinorStart date: Aug 5, 2026 to Aug 6, 2026v25
MinorStart date: Aug 4, 2026 to Aug 5, 2026v24
MinorStart date: Aug 3, 2026 to Aug 4, 2026v23
MinorStart date: Aug 2, 2026 to Aug 3, 2026v22
MinorStart date: Jul 30, 2026 to Aug 2, 2026v21
MinorStart date: Jul 29, 2026 to Jul 30, 2026v20
MinorStart date: Jul 28, 2026 to Jul 29, 2026v19
MinorStart date: Jul 27, 2026 to Jul 28, 2026v18
MinorStart date: Jul 26, 2026 to Jul 27, 2026v17
MinorStart date: Jul 23, 2026 to Jul 26, 2026v16
MinorStart date: Jul 22, 2026 to Jul 23, 2026v15
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background:
Myeloid cells are a type of immune cell found in most tumors. Interleukin 12 (IL-12) is a protein that helps the immune system kill tumor cells. Researchers want to know if myeloid cells that have been genetically engineered to produce IL-12 (IL-12 GEMys) can activate the immune system to attack cancer cells in solid tumors.
Objective:
To test IL-12 GEMys in people with cancer.
Eligibility
People aged 18 years and older with cancer that returned or failed to respond to treatment.
Design:
Participants will be screened. They will have a physical exam with blood tests. They will have tests of their heart and lung function. They will have imaging scans of their tumors. A sample of tumor tissue may be taken.
Participants will have daily injections for few days to prepare them to undergo leukapheresis: Blood will be taken from the body through a needle inserted into a vein. The blood will pass through a machine that separates out stem cells. The remaining blood will be returned to the body through a different needle. The collected stem cells will be modified in a lab to create IL-12 GEMys.
Participants will check in to the hospital. They will receive drugs for 5 days to prepare their body for the treatment. Then they will have their own IL-12 GEMys infused through a needle inserted into a vein. They will stay in the hospital until they are well enough to go home. This may be 7 to 14 days or longer.
Some participants may receive a second treatment with IL-12 GEMys within 2 years after the first.
Participants will have follow-up visits for about 5 years. These will include imaging scans and blood tests.
...